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Abstract
Background: The Belgian HIV epidemic is largely concentrated among men who have sex with men and
Sub-Saharan Africans. We studied the continuum of HIV care of those diagnosed with HIV living in Belgium and its
associated factors.
Methods: Data on new HIV diagnoses 2007–2010 and HIV-infected patients in care in 2010–2011 were analysed.
Proportions were estimated for each sequential stage of the continuum of HIV care and factors associated with
attrition at each stage were studied.
Results: Of all HIV diagnosed patients living in Belgium in 2011, an estimated 98.2 % were linked to HIV care, 90.8 %
were retained in care, 83.3 % received antiretroviral therapy and 69.5 % had an undetectable viral load (<50 copies/ml).
After adjustment for sex, age at diagnosis, nationality and mode of transmission, we found lower entry into care in
non-Belgians and after preoperative HIV diagnoses; lower retention in non-Belgians and injecting drug users; higher
retention in men who have sex with men and among those on ART. Younger patients had lower antiretroviral therapy
uptake and less viral suppression; those with longer time from diagnosis had higher ART uptake and more viral
suppression; Sub-Saharan Africans on ART had slightly less viral suppression.
Conclusions: The continuum of HIV care in Belgium presents low attrition rates over all stages. The undiagnosed
HIV-infected population, although not precisely estimated, but probably close to 20 % based on available survey and
surveillance results, could be the weakest stage of the continuum of HIV care. Its identification is a priority along with
improving the HIV care continuum of migrants.
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Background
The use of ART (antiretroviral therapy) in HIV-infected
patients has shown its efficiency not only in improving
the individual outcomes of patients but also in reducing
the transmission of HIV [1–3]. A persisting challenge of
the HIV epidemic is reaching the highest proportion of
overall viral suppression among people living with HIV
(PLHIV) in order to impact HIV transmission [3, 4].
In Belgium the epidemic is largely concentrated among
men who have sex with men (MSM) - mainly of Belgian or
European nationality - and Sub-Saharan African (SSA) men
and women. The number of annual new HIV diagnoses
increased by half between 1997 and 2003 and has since
remained stable at 1000 to 1200 new cases per year [5].
The number of PLHIV has steadily increased since
introduction of ART. Recent surveys conducted in two
large Belgian cities have shown an HIV prevalence
among MSM ranging from 6 [6] to 12 % (C. Noestlinger,
personnal communication, March 2015). In a survey
among SSA migrants in Antwerp, HIV prevalences of
3 % in men and 6 % in women were found [7].
Services for HIV testing in Belgium are available either
in primary care, secondary care (specialized outpatient
clinics), hospitals and decentralized projects. Three Aids
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Reference Centers (ARC) are funded to perform low
threshold and free anonymous testing. Outreach pro-
grams are set up to better target HIV high risk groups.
These programs are organized by the ARCs or through a
collaborative effort with NGOs working with the specific
target population. Compared to other European coun-
tries [8], Belgium has a high and relatively stable rate of
HIV testing, with a total of 695.433 HIV tests performed
(62 per 1000 inhabitants) in 2013.
Access to HIV care in Belgium is, in principle, ensured
to all HIV-infected individuals through the compulsory
national health insurance. Antiretroviral therapy is reim-
bursed when a patient’s CD4 count is below or equal to
500 cells/mm3 or below 25 % and in case of clinical
symptoms. There is no national guideline for HIV care,
clinicians follow the guidelines of the European AIDS
Clinical Society for clinical and laboratory monitoring
[9]. Undocumented migrants may access care through a
procedure called urgent medical help [10]. Nevertheless,
the key populations in the Belgian HIV epidemic, MSM
and migrants, differ in socio-demographic characteristics
such as nationality, migrant status and social context
which may influence their access to HIV testing and care.
In order to reach the best outcomes for HIV-infected
individuals and potentially reduce HIV transmission, a
continuum of HIV care services needs to be ensured.
The HIV care cascade is an illustration of the continuum
of HIV care built on estimates of the size of the HIV-
infected population at different stages: infection, diagno-
sis, linkage to care, retention in care, ART uptake and
viral load suppression. This approach allows pinpointing
possible attrition along the continuum of care and may
help to compare and prioritize prevention and care strat-
egies [3]. These results also inform on the potential for
domestic transmission of HIV through the estimation of
the HIV-infected population without suppressed VL
residing in the country. Several countries have already
reported their domestic HIV care cascade [11–14]. These
were built on available national surveillance data and survey
results combined with estimates obtained by mathematical
data modelling.
In this study, we estimated the proportion in each
stage of the continuum of HIV care in Belgium among
diagnosed PLHIV and analysed factors associated with
attrition at each respective stage.
Methods
Data sources and setting
Estimates of the continuum of care from HIV diagnosis
to undetectable viral load (VL) were calculated by ana-
lysing combined data from two surveillance systems
managed by the Scientific Institute of Public Health
(WIV-ISP): the registry of new HIV diagnoses and the
Belgian HIV Cohort. The national registry of new HIV
diagnoses [5] records all newly diagnosed confirmed
HIV cases based on exhaustive reporting by the Belgian
AIDS Reference Laboratories (ARLs). The Belgian HIV
Cohort study [15] collects data on HIV-infected patients
in care including data on viral load measurements
recorded by the ARLs and CD4 counts and ART data
recorded by the ARCs from 2007 onwards. All HIV-
infected patients in medical care in Belgium have their
VL analysed in the ARLs and around 75–80 % of
patients have been followed in the ARCs in recent years.
The WIV-ISP is the legal entity in charge of the HIV
and AIDS surveillance activities (Royal decree of 8 October
1996). The HIV surveillance system was approved by
the ethical committee of Ghent University hospital and
authorized by the Privacy Commission. Strict attention to
confidentiality is present at every stage of data collection,
analysis and storage.
Definitions
Proportions in each stage of the continuum of HIV care
were estimated using the following definitions.
Linkage to HIV care was defined as having at least one
VL or CD4 count recorded within 1 year of HIV diagno-
sis, with a window of 7 days for VL records to prevent
incorrectly counting VL measurements performed at the
time of diagnosis as initial HIV care visit.
Retention in HIV care was defined as the proportion
of patients in care in 2010, those having one CD4 or VL
measurement during that year, who had at least one
record of CD4 or VL in 2011.
Proportions of patients on ART and with suppressed
VL were measured among those in care in the ARCs in
2011. ART was defined as a record of ART prescription
at the end of 2011. Suppressed VL was defined as the
last measured VL <50 copies/mL.
Continuum of HIV care
Proportions calculated for each stage of the continuum
of HIV care were combined to obtain the distribution of
the diagnosed HIV individuals living in Belgium in 2011
by stage of the continuum.
The total diagnosed HIV population living in Belgium
was obtained by summing the estimated population
retained in care in 2011 with the estimated number of
HIV-positive persons diagnosed but not linked to care in
2011 and the estimated number of persons previously in
HIV care but not retained in care in 2011. The distribu-
tion of the diagnosed HIV population through the stages
of the continuum of care is schematized in Fig. 1.
Using 2007 data, we first estimated the proportion of
patients that entered in care later than 1 year after diag-
nosis. We then applied this proportion of late entry into
care to patients diagnosed in the years following 2007
to obtain an estimate of the total number of patients
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entering late in care. From this total we subtracted those
who entered in care before the end of 2011 in order to ob-
tain the estimated number of diagnosed patients not
linked to care and expected to enter in care after 2011.
Next we estimated for the patients in care in 2007 and
not retained in care after 1 year, the proportion who re-
entered care later. Using a similar computation, the
number of patients entering back in care was calculated
for the years following 2007. From the cumulative total,
we subtracted patients already re-entered in care by the
end of 2011 in order to obtain the estimated number of
patients not retained in care and expected to re-enter
care after 2011.
Patients estimated to never enter or re-enter care were
considered as having left the country. We also hypothe-
sised that persons diagnosed before 2007 were not
expected to enter in care after 2011.
The next stages of the continuum of HIV care were
estimated by applying the proportions of patients on
ART and with VL suppression to the population in HIV
care in 2011.
Data management and statistics
Databases were merged using a unique patient identifier.
Identification of duplicate patient records was performed
by comparing the following set of variables: gender,
initials, date of birth, date of HIV diagnosis, presumed
mode of transmission, nationality, place of residence and
laboratory results.
Socio-demographic factors, time period since diagnosis
and CD4 count at first medical consultation (±31 days)
were analysed for association with each stage of the
continuum of HIV care by multivariate logistic regres-
sion. Analyses were performed with Stata 10.1.
Results
A total of 4117 individuals diagnosed with HIV between
2007 and 2010 were analysed for entry in care. Of
11,781 patients in care in 2010, 112 patients died before
end of 2011, leaving 11,669 patients analysed for retention
in care. ART uptake and VL levels were analysed for 9710
patients in care in the ARCs in 2011. Newly diagnosed in-
dividuals and patients in care shared the following similar
socio-demographic characteristics (Table 1). Around two
thirds were men and median age at diagnosis was approxi-
mately 35 years. Probable acquisition of HIV by sexual
transmission was reported by more than 90 % of the
patients with available information. Nearly half of the
patients with reported nationality were Belgians and one
third originated from countries in Sub-Saharan Africa.
Among newly diagnosed individuals, 87.0 % entered in
HIV care within 1 year of diagnosis. This proportion in-
creased over the years (2007: 84.5 %, 2008: 87.4 %, 2009:
87.0 %, 2010: 89.0 %; p < 0.001). Linkage to care was
made within 3 months following HIV diagnosis for
88.1 % of those who entered in HIV care (Fig. 2). Median
CD4 value at first medical contact was not significantly
different between those who entered in care in the first
3 months following diagnosis (414 CD4 cells/mm3 (IQR:
248–595)) and those entered in care later (403 CD4
cells/mm3 (IQR: 221–585)).
Of those in care in 2010 and not reported to have
died, 92.2 % were retained in care in 2011. Among those
Fig. 1 Diagram representing the distribution of the HIV diagnosed population within the continuum of HIV care
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in care in the ARCs, 84.6 % were receiving ART, of whom
83.4 % were virally undetectable.
Factors associated with entry, time to entry and retention
in care
Univariate analyses show that entry and retention in care
were lower among women and non-Belgians and higher
among MSM (Table 2). Patients infected through inject-
ing drug use (IDU) had lower retention in care. After
adjustment for sex, age at diagnosis, nationality and
mode of transmission, entry and retention in care
remained lower among non-Belgians, retention was still
higher among MSM and lower among IDU. Individuals
tested for preoperative reasons had lower entry in care,
they represented only 2.6 % of those with available data
on reasons for testing, and presented significantly longer
delay between diagnosis and entry in care than patients
with all other reasons for testing (median time: 32 vs
14 days, p < 0.001). Linkage to care within 3 months of
diagnosis was slightly lower among non-Belgians than
Belgians (respectively 88.2 and 90.5 %; p = 0.049). Longer
time period since HIV diagnosis and ART uptake were
both independently associated with higher retention in
care.
Factors associated with ART uptake and viral suppression
among those on ART
Univariate analyses show that, younger age was associ-
ated with lower ART uptake and less viral suppression
on ART, MSM had lower ART uptake and more viral
suppression, those diagnosed for longer had higher ART
uptake and higher VL suppression. Patients diagnosed
for clinical reasons and with lower CD4 count at first
contact had higher ART uptake. Sub-Saharan African
patients on ART had less VL suppression (Table 3).
Multivariate analyses show that younger age remained
associated with lower ART uptake and less VL suppres-
sion. HIV testing requested for clinical reasons and
lower CD4 count at first contact remained associated
with higher ART uptake and Sub-Saharan African
nationality with less VL suppression. Those with longer
time from diagnosis had higher ART uptake and more
frequent VL suppression. Multivariate analyses on ART
uptake were adjusted for CD4 count at first medical
Table 1 Baseline characteristics of HIV-infected individuals diagnosed between 2007 and 2010 and of patients in medical care in
2010 in Belgium
Characteristic Individuals diagnosed with HIV, 2007–2010 (N = 4117) Patients in medical care, 2010 (N = 11,669)
Sex
Male 2715 (66.0 %) 7259 (62.2 %)
Female 1397 (33.9 %) 4409 (37.8 %)
Unknown 5 (0.1 %) 1 (0.0 %)
Age at diagnosis
Median age (IQR), years 36 (29–44) 34 (28–41)
Way of transmission
Heterosexual 1566 (38.0 %) 4560 (39.1 %)
MSM 1362 (33.1 %) 3149 (27.0 %)
IDU 63 (1.5 %) 217 (1.9 %)
Other 109 (2.7 %) 399 (3.4 %)
Unknown 1017 (24.7 %) 3344 (28.7 %)
Nationality
Belgian 1401 (34.0 %) 4210 (36.1 %)
Sub-Saharan African 1107 (26.9 %) 3242 (27.8 %)
European 391 (9.5 %) 665 (5.7 %)
Other 259 (6.3 %) 548 (4.7 %)
Unknown 959 (23.3 %) 3004 (25.7 %)
Fig. 2 Distribution of delay between HIV diagnosis and first medical
contact in HIV care (recorded CD4 or VL) among patients entered in care
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visit. As time since ART initiation was not available, it
could not be taken into account in the multivariate
analyses on VL suppression.
Proportions of diagnosed patients along the continuum
of HIV care in Belgium
We estimated that 11,478 patients were retained in HIV
care in 2011 by applying the proportion of retention in
HIV care of 92.2 % observed in 2010 to the 12,449 HIV+
patients with at least one laboratory record in 2011.
The proportion of late entry in care of 4.7 % observed
in the 2007 data was applied to persons diagnosed in the
years following 2007. After subtraction of those already
entered in care, we found that 221 patients were
expected to enter in care after 2011 (see detailed compu-
tation in Additional file 1).
Table 2 Factors associated with entry in care (2007–2010) and retention in care (2010–2011) among HIV-infected patients in
Belgium
Entry in care Retention in care
Characteristic Entry OR for no entry
(95 % CI)
AORa for no entry
(95 % CI)
Retained OR for no retention
(95 % CI)
AORa for no retention
(95 % CI)
Sex
Male 88.8 % 1 1 92.9 % 1 1
Female 83.9 % 1.52 (1.26–1.83) 0.83 (0.58–1.19) 91.0 % 1.30 (1.13–1.49) 0.82 (0.66–1.04)
Age at diagnosis
<40 years 87.1 % 1 1 94.1 % 1 1
≥40 years 87.0 % 1.01 (0.84–1.22) 0.91 (0.67–1.24) 93.9 % 1.02 (0.86–1.23) 1.01 (0.81–1.25)
Way of transmission
Heterosexual 91.4 % 1 1 91.8 % 1 1
MSM 94.6 % 0.61 (0.45–0.82) 0.97 (0.62–1.51) 95.1 % 0.56 (0.45–0.70) 0.59 (0.45–0.78)
IDU 85.7 % 1.77 (0.85–3.66) 1.69 (0.71–4.05) 85.8 % 1.87 (1.22–2.86) 2.01 (1.27–3.17)
Nationality
Belgian 95.7 % 1 1 95.8 % 1 1
SSA 88.8 % 2.82 (2.05–3.88) 3.36 (2.14–5.27) 92.8 % 1.74 (1.42–2.12) 1.50 (1.16–1.93)
European 88.5 % 2.91 (1.94–4.35) 2.43 (1.52–3.90) 91.7 % 2.03 (1.48–2.78) 1.88 (1.35–2.61)
Other 88.0 % 3.04 (1.93–4.79) 3.01 (1.81–5.01) 93.4 % 1.58 (1.09–2.29) 1.43 (0.97–2.10)
Reason for testing
Patient’s request 93.3 % 1 1 95.0 % 1 1
Clinical arguments 93.5 % 0.97 (0.69–1.36) 0.90 (0.61–1.32) 94.3 % 1.15 (0.88–1.50) 1.01 (0.77–1.34)
Preoperative 79.2 % 3.68 (2.01–6.73) 3.91 (2.03–7.53) 93.1 % 1.42 (0.82–2.46) 1.31 (0.74–2.32)
Other 90.3 % 1.51 (1.04–2.20) 0.98 (0.63–1.53) 92.9 % 1.46 (1.09–1.95) 1.20 (0.89–1.63)
CD4 at first visit
CD4≥350 / / / 93.2 % 1 1
CD4≥200 & <350 / / / 91.3 % 1.30 (0.90–1.86) 1.12 (0.74–1.69)
CD4 < 200 / / / 91.5 % 1.28 (0.87–1.86) 1.16 (0.76–1.77)
Time since HIV diagnosis
<1 year / / / 90.0 % 1 1
1 – <5 years / / / 93.9 % 0.59 (0.47–0.74) 0.55 (0.42–0.72)
5 – <10 years / / / 95.4 % 0.44 (0.34–0.56) 0.42 (0.32–0.56)
≥10 years / / / 95.7 % 0.41 (0.32–0.51) 0.40 (0.31–0.53)
ART
Not on ART end 2009 / / / 93.5 % 1 1
On ART end 2009 / / / 96.6 % 0.50 (0.39–0.64) 0.45 (0.34–0.61)
p < 0.05, statistically significant variables presented in boldface
aAdjusted for sex, age at diagnosis, nationality, way of transmission
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Table 3 Factors associated with ART uptake and VL suppression among HIV-infected patients in care in the ARCs (2011), Belgium
ART uptake VL suppression
Characteristic On ART OR for no ART uptake
(95 % CI)
AORa for no ART uptake
(95 % CI)
AORb for no ART uptake
(95 % CI)
Undetectable VL OR for detectable VL
(95 % CI)
AORa for detectable VL
(95 % CI)
Sex
Male 84.5 % 1 1 1 83.7 % 1 1
Female 84.9 % 0.97 (0.87–1.09) 1.38 (1.14–1.67) 1.16 (0.85–1.58) 82.9 % 1.06 (0.93–1.19) 0.84 (0.70–1.01)
Age at diagnosis
<40 years 84.0 % 1 1 1 82.3 % 1 1
≥40 years 85.5 % 0.89 (0.78–1.01) 0.88 (0.76–1.02) 0.74 (0.60–0.91) 85.2 % 0.81 (0.70–0.93) 0.83 (0.71–0.97)
Way of transmission
Heterosexual 85.9 % 1 1 1 82.6 % 1 1
MSM 81.8 % 1.36 (1.19–1.55) 1.54 (1.27–1.88) 0.98 (0.73–1.32) 84.8 % 0.85 (0.74–0.98) 0.88 (0.72–1.07)
IDU 85.6 % 1.02 (0.66–1.59) 1.01 (0.64–1.60) 0.75 (0.27–2.11) 82.5 % 1.01 (0.65–1.56) 1.04 (0.66–1.65)
Nationality
Belgian 83.8 % 1 1 1 85.1 % 1 1
SSA 86.4 % 0.81 (0.71–0.93) 0.87 (0.73–1.05) 0.89 (0.65–1.21) 81.3 % 1.31 (1.14–1.52) 1.25 (1.04–1.51)
European 82.5 % 1.10 (0.88–1.37) 1.14 (0.91–1.44) 0.84 (0.61–1.15) 84.2 % 1.07 (0.83–1.38) 1.01 (0.77–1.32)
Other 81.9 % 1.14 (0.90–1.45) 1.13 (0.89–1.45) 1.17 (0.81–1.67) 81.1 % 1.33 (1.03–1.73) 1.21 (0.92–1.59)
Reason for testing
Patient’s request 76.7 % 1 1 1 82.6 % 1 1
Clinical arguments 86.2 % 0.53 (0.45–0.62) 0.57 (0.48–0.67) 0.77 (0.61–0.97) 82.9 % 0.98 (0.82–1.18) 0.96 (0.79–1.16)
Preoperative 78.8 % 0.89 (0.62–1.27) 0.95 (0.64–1.40) 1.82 (0.95–3.52) 88.2 % 0.64 (0.38–1.07) 0.65 (0.38–1.11)
Other 83.5 % 0.65 (0.54–0.78) 0.73 (0.60–0.89) 0.92 (0.68–1.25) 83.7 % 0.93 (0.75–1.15) 0.87 (0.69–1.10)
CD4 at first visit
CD4≥350 58.5 % 1 1 / 76.5 % 1 1
CD4≥200 & <350 88.0 % 0.19 (0.15–0.25) 0.19 (0.14–0.26) / 78.2 % 0.91 (0.70–1.17) 0.83 (0.62–1.10)
CD4<200 94.0 % 0.09 (0.06–0.13) 0.09 (0.06–0.14) / 74.6 % 1.10 (0.87–1.41) 1.03 (0.78–1.37)
Time since HIV diagnosis
<1 year 54.2 % 1 1 1 49.2 % 1 1
1 – <5 years 78.3 % 0.33 (0.28–0.39) 0.32 (0.27–0.39) 0.26 (0.21–0.33) 81.5 % 0.22 (0.18–0.27) 0.22 (0.17–0.27)
5 – <10 years 89.3 % 0.14 (0.12–0.17) 0.13 (0.11–0.16) 0.12 (0.07–0.19) 88.4 % 0.13 (0.10–0.16) 0.12 (0.09–0.15)
≥10 years 94.5 % 0.07 (0.06–0.08) 0.06 (0.05–0.07) / 85.9 % 0.16 (0.13–0.20) 0.14 (0.11–0.18)
p < 0.05, statistically significant variables presented in boldface
aAdjusted for sex, age at diagnosis, nationality, way of transmission














Re-entry in care among patients not retained in care
for 1 year after 2007 was estimated at 39.5 %. By apply-
ing this proportion of re-entry to the patients not
retained in care in the following years and then subtract-
ing those already re-entered in care, we estimated that
940 persons were expected to re-enter in care after 2011
(see detailed computation in Additional file 1).
After combining these results, the population of diag-
nosed HIV patients living in Belgium at the end of 2011
(n = 12,639) was distributed as follows: 11,478 patients
(90.8 %) were estimated to be retained in HIV care, 221
(1.8 %) were not linked to HIV care and 940 (7.4 %) were
not retained in HIV care.
The estimated proportions of 84.6 % of patients in care
on ART of whom 83.4 % of patients with viral suppres-
sion were applied to the population in HIV care in 2011
(n = 12,449). We estimated 83.3 % (n = 10,532) of the
diagnosed HIV population living in Belgium to be on
ART and 69.5 % (n = 8784) to have suppressed VL.
The continuum of HIV care of the diagnosed HIV
patients living in Belgium is illustrated in Fig. 3.
Discussion
The continuum of HIV care in Belgium presents low at-
trition rates over all stages of care with 69 % of all HIV
diagnosed individuals in Belgium having an undetectable
viral load.
HIV care leans on well-organized specialized struc-
tures, the ARLs and the ARCs, that offer access to com-
prehensive care including free psycho-social support,
counselling and fully reimbursed antiretroviral therapy.
In addition, these specialized structures have developed
collaborations with prevention and testing associations
that contribute to a more efficient linkage to HIV care.
Vulnerable populations such as non-Belgians and IDU
present lower entry and retention in HIV care but, once
retention in care is ensured, their access to ART are
similar to other HIV-infected individuals. Yet, poorer
virological outcome was observed among SSA migrants.
Similar findings for lower entry and retention of these
populations are reported in other European studies [13,
16, 17], and lower ART uptake or viral suppression
among migrants was observed in Spain [18], UK [19]
and France [20]. IDU represent only 2.5 % of the HIV-
infected patients in care in Belgium with a sustained low
HIV transmission reported over the last years [5] due to
accessible harm reduction programs. The limited number
of IDUs enables more intensive follow-up and counselling
to prevent comorbidities and onward HIV transmission
by unsafe injecting practices.
Additionally, more frequent delayed diagnoses ob-
served in these two populations (migrants and IDUs)
worsen the poorer outcomes observed along the con-
tinuum of care [5, 21]. For migrants whose infection was
acquired in their country of origin, the diagnosis delay
may precede the arrival in Belgium.
Migrants’ lower entry and retention in HIV care may
be due to emigration after HIV diagnosis or barriers to
access care for those remaining in Belgium. Attrition is
similar between Europeans and non-Europeans, but
consequences of emigration out of Belgium in terms of
access and continuum of care greatly differ. While
West-Europeans have reliable access to care in their
country of origin, this may not be true for East-European
and non-European migrants. In fact, reported ART cover-
age among those in need of ART in numerous non-
European or East-European countries was below 50 % in
2012 [22] and potentially even lower for stigmatized popu-
lations like MSM and IDU. This study does not allow dif-
ferentiation between documented and undocumented
migrants although it is mainly undocumented migrants
that face disproportionate barriers to medical care [10].
The HIV epidemic in Europe is influenced by its evolution
in other countries through travel and migration [23]. The
continuum of care for this mobile population could be
improved by developing cross-border and national tools
to facilitate adequate and individual-tailored care of the
migrant population diagnosed with HIV in Belgium.
The results also underline a gap in linkage to care
among patients diagnosed for pre-operative reasons due
to longer delay between initial diagnosis and entry in
care. Timely communication of HIV diagnosis to the pa-
tient in specific settings like pre-operative testing would
be facilitated by training of caregivers on sexual health
counselling and HIV screening. These interventions are
part of the recommendations of the Belgian National
HIV plan that has been launched in 2013 [24].
Factors impacting ART uptake and VL suppression
were logical indicators of the clinico-immunological
situation of the patient: duration since HIV diagnosis,
older age with associated co-morbidity, HIV diagnosis
Fig. 3 Estimated percentage of diagnosed HIV individuals living in
Belgium by stage of the continuum of HIV care, 2011
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for clinical reason and low CD4 count. None of the
socio-demographic factors studied impacted ART uptake
and VL suppression, except the SSA nationality that was
associated with lower VL suppression, although the dif-
ference with Belgians was small. These results suggest
that ARV treatment needs are equally covered for all
patients having access to regular HIV care. Suboptimal
ART adherence potentially related to socio-economic
factors [18] might explain the slightly lower VL suppres-
sion among SSA. Other reasons for non VL suppression
might be ARV resistance or recent ART initiation at the
time of VL measurement but this information was not
collected.
Patients on ART have a higher retention in care as
also observed in another cohort [17].
The attrition observed along the continuum of HIV
care should not be interpreted globally but according to
the stage at which it occurs. Indeed, its consequences,
both in terms of individual prognosis and potential for
HIV transmission are different in early and late stages of
the continuum of care. In the early stages of the con-
tinuum, HIV-infected individuals who are not diagnosed,
not linked or not retained in care have a higher risk of
delay in ART initiation, complications and co-morbidities
and have no access to regular psycho-social support and
counselling. Hence, attrition in the early stages is associated
with a higher likelihood of unfavourable clinical evolution
and onward transmission [25]. In the late stages of the con-
tinuum, patients retained in regular HIV care in Belgium
have access to counselling services and timely ART initi-
ation based on their viro-immunological status and their
presumed need for ART to prevent transmission. Those
untreated or presenting detectable VL among this carefully
monitored population are considered as lost in the late
stages of the continuum of care according to the cascade
analysis definition. Yet, the likelihood of them causing
onward transmission or having an unfavourable clinical
evolution is lower than among the population lost in
the early stages of the continuum [26].
In other European cascades of HIV care, reported pro-
portions of VL suppression among those diagnosed with
HIV ranged from 70 % (<500 copies/mL) in Sweden and
Denmark in 2010 [13], 72 % (<50 copies/mL) in UK in
2011 [12] and 64 % (<50 copies/mL) in France in 2010 [14].
Given the various definitions used for the study population
and for each stage of the continuum of care, international
comparison is difficult. Nevertheless Belgian results are
close to previously reported European proportions while
differing strongly from the recently reported proportion of
35 % of those diagnosed achieving viral suppression (<200
copies/mL) in the United States in 2011 [11].
The UNAIDS has recently published global targets of
90 % of PLHIV knowing their status, 90 % of those re-
ceiving ART and 90 % of those having suppressed VL by
2020 [27]. The results presented here show that Belgium
is not yet fulfilling these targets. With the recent release
of the results of the START study supporting added
benefit of offering treatment to everyone with HIV [28]
however, we may expect an increase in the proportion of
patients on ART in the coming years. This might also
increase the retention in HIV care among recently diag-
nosed patients, who will initiate ART immediately, as
ART uptake was associated with higher retention in HIV
care. Efforts should then concentrate on the diagnosis of
persons unaware of their HIV infection in order to initi-
ate their treatment earlier.
Our understanding of the continuum of HIV care is
limited by the lack of precise national estimates of
PLHIV unaware of their status. In Europe, 30 % of
PLHIV were estimated to be unaware of their infection,
with large variations between countries [23]. In Belgium,
a local survey limited in sample size and geographical
coverage, reported a proportion of undiagnosed HIV-
infected MSM of 14 % in 2010 [8]. In the national STI
sentinel network, the proportion of patients co-infected
with HIV and STI ignoring their HIV status was 14 % in
2011 [29]. Among migrants newly diagnosed in 2013,
93 % of those with known date of arrival (70 %) came to
Belgium in the 2 year period preceding the diagnosis in
Belgium [30], implying a limited period of residence in
Belgium as undiagnosed. Based on these various sources
of information, the proportion of undiagnosed PLHIV
residing in Belgium is probably not higher than 20 %.
This approximate estimate is similar to the proportions
of 24 and 19 % found in UK and France respectively [14,
31, 32]. As those infected and remaining undiagnosed
for long end up being diagnosed late, the similar propor-
tion of late diagnoses in Belgium as compared to these
two countries [8], suggests that the pool of undiagnosed
PLHIV in Belgium is not larger than in surrounding
countries. When including this estimate in the con-
tinuum of care, the proportion of individuals with sup-
pressed VL among all PLHIV residing in Belgium is
estimated at 56 %. The proportion of 20 % of PLHIV un-
aware of their HIV infection could represent the weakest
stage of the Belgian HIV care continuum. Given the low
attrition observed along the subsequent steps of the con-
tinuum of HIV care, identifying the undiagnosed PLHIV
could be the intervention with potentially the highest
impact on transmission and patient prognosis in Belgium,
this coincides with observations made in other countries
such as UK, Canada and the US [25, 33]. A project aiming
at estimating and characterizing undiagnosed HIV-infected
populations by mathematical modelling of routine HIV sur-
veillance data will be conducted in the coming years. These
results will be used to target HIV testing to groups that
require it the most. Among those undiagnosed, recently
HIV-infected individuals appear to be disproportionately
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involved in onward HIV transmission, likely due to in-
creased viral concentrations, higher viral fitness and more
risky behaviour around time of HIV acquisition [2, 34]. In
Belgium, the proportion of recently infected individuals
among those diagnosed was estimated at 37.5 % in 2012
[35], higher than in UK and France where it ranged from
22 to 30 % [14, 31, 32]. HIV testing strategies, tailored to
identify those recently infected as well as those who have
remained undiagnosed for long, should be maintained and
expanded. Alternative decentralized testing strategies
should be further developed along with interventions to
reduce missed opportunities for earlier HIV diagnosis in
medical settings.
There are some limitations in this study. The results
do not inform on the outcomes of the patients after they
have left the country. In addition, HIV-infected citizens
of surrounding countries are also difficult to capture in
the continuum of care as they might be diagnosed and
followed in their own country whilst actively contribut-
ing to the local epidemic.
We used 2007 data to estimate the proportions of late
entry and re-entry into HIV care as time of follow-up for
these patients was at least 4 years. We assumed these
proportions did not change over the next years and ap-
plied them to estimate the number of patients with late
entry and with re-entry during the following years. How-
ever as linkage to care within 1 year improved slightly
after 2007, the proportion of patients expected to enter
late in HIV care in the following years might be lower.
Hence the population of persons diagnosed and not linked
to HIV care living in Belgium might be slightly overesti-
mated based on the proportions estimated in 2007.
This analysis was strongly dependent of a good match
between HIV diagnosis data and laboratory data through
identifiers built on patients’ date of birth and initials. Er-
rors on these identifiers are not excluded but they are
likely to represent a very low proportion of the entire
dataset thanks to the thorough annual monitoring.
The analyses of the early stages of the continuum of
care included all the individuals diagnosed with HIV and
in care in Belgium. Only the analyses on ART coverage and
VL suppression were restricted to the patients retained in
care in the ARCs. The ARC population differed significantly
from those outside of the ARCs for some characteristics
such as gender (women: 36 % vs 42 %), nationality
(Sub-Saharan Africans: 36 % vs 43 %; Belgians: 50 % vs
45 %), mode of transmission (MSM: 40 % vs 30 %; het-
erosexuals: 54 % vs 56 %) and median age (34 years vs
32 years). Given the small proportion of patients retained
in care outside the ARCs (20 %) and age being the single
characteristics associated with ART uptake and VL
suppression, the estimates obtained from the ARC popula-
tion could be used as estimates for the whole study
population.
Information on age and sex was missing in less than
0.5 % of the cases, data on mode of transmission and na-
tionality were missing for approximately 30 % of cases,
and up to 60 % for those who never entered in care. The
high proportion of missing information among the latter
is foreseeable given their medical contact limited to the
diagnosis consultation. Such cases included a majority of
patients who emigrated after diagnosis as any other pa-
tient remaining in Belgium would end up entering in
care, thus higher completeness of such data would prob-
ably reinforce the strong association observed between
no entry and non-Belgian nationality.
Conclusions
The continuum of HIV care in Belgium is well ensured
although some barriers to access care for migrants, pos-
sibly linked with their legal status, are observed. Mi-
grants who emigrated after diagnosis or those who are
in care in neighbouring countries were not captured by
this analysis, although these are major actors in the dy-
namic of the epidemic. Strategies to improve identification
of the undiagnosed PLHIV is a priority. Together with the
improvement of the HIV care continuum of migrants,
these strategies would contribute to move closer to the
ambitious “90-90-90” global targets of the UNAIDS [27].
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